Amphastar Pharmaceuticals, Inc.
AMPHHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Amphastar Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States,. With a market capitalization of $975.4M, it sits in small-cap territory. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Market Cap
$975.4M
Beta
0.92
P/E (TTM)
13.57
P/E (Fwd)
7.21
EPS (TTM)
$1.69
EPS (Fwd)
$3.18
ROE
10.3%
ROA
5.1%
Cash
$290.1M
Total Debt
$688.3M
Free CF
$230.1M
52W Change
-18.4%
Annual Financials
Cash vs Debt
Where AMPH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, AMPH finished 12.14% above its 150-day moving average ($21.17) and 5.32% above its 200-day moving average ($22.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMPH overbought or oversold?
At the September 3, 2026 close, AMPH's RSI(14) was 90.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Amphastar Pharmaceuticals, Inc. carries $688.3M in total debt against $290.1M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $230.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 10.3% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $499.0M (2022) to $719.9M (2025), reflecting a 44% increase over the period.
Investors considering Amphastar Pharmaceuticals, Inc. should weigh the typical risks associated with AMPH's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Amphastar Pharmaceuticals, Inc. and its sector.